Hormonal
Epicardial adipose tissue (EAT) contributes to Heart Failure with Preserved Ejection Fraction (HFpEF) through two distinct mechanisms: mechanical pericardial restraint and local inflammatory/fibrotic secretion.
For patients with HFpEF, managing epicardial fat is crucial. While general weight loss helps, specific interventions like bariatric surgery or Mediterranean-style diets have been shown to reduce EAT volume and improve heart mechanics. Monitoring EAT via imaging can help assess risk and treatment efficacy.
EAT can theoretically be a contributor to obesity-related HFpEF by either mechanically enhancing pericardial restraint and/or through local secretory effects from its direct contact with the underlying myocardium causing adjacent ventricular and atrial remodelling.
Why this rating
Supported by multiple observational studies, longitudinal data, and physiological mechanisms, though causality is debated.
Source
Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Mary-Tiffany Oduah et al. · Cardiac failure review · 2023
DOI 10.15420/cfr.2022.25
More from this paper
- Bariatric surgery is the most effective intervention for reducing epicardial fat volume and improving HFpEF outcomes, superior to modest lifestyle changes.Good
- A Mediterranean-style diet with high unsaturated fats and low carbohydrates reduces epicardial fat volume, whereas a standard low-calorie diet and exercise alone do not.Good
- SGLT2 inhibitors reduce epicardial fat volume independently of significant weight loss, suggesting a direct lipolytic effect on epicardial tissue.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →